Introduction:
Despite the emergence of new
treatments for HCV
genotype 3 (HCV G3), there is still a lack of data about this particular subgroup in
Brazil. Our objective was to describe clinical and sociodemographic variables and
treatment profile of HCV G3 Brazilian
patients.
Methods:
This was a descriptive,
retrospective study, performed in a specialized center for HCV
treatment in the South Region of
Brazil.
Medical records of
patients diagnosed with HCV G3 were reviewed to collect clinical, sociodemographic, and
treatment information.
Results:
Participants included total of 564
patients, with a mean age of 59.3 years (SD = 10.5).
Cirrhosis was present in 54.4% of
patients. The most common coexisting conditions were systemic arterial
hypertension (36.6%) and
diabetes mellitus (30%). Regarding
treatment, 25.2% of the
patients were
treatment-naïve and 74.8% were currently
under treatment (11.6%) or had received a previous
treatment (87%). The most frequent ongoing
treatment was
sofosbuvir + daclatasvir (±
ribavirin) (87.8%). Of the 388
patients who had at least one previous
treatment, 67% achieved
sustained virologic response in the last
treatment. Caucasian /
white, non-obese, transplanted
patients, those with longer
time since
diagnosis and with
cirrhosis were more likely to receive
treatment, according to
multivariate analysis.
Patients with
hepatocellular carcinoma were 64.1% less likely to be on
treatment during the study period than those without this condition;
patients with
chronic kidney disease were 2.91-fold more likely to have an interruption of
treatment than those without this condition.
Conclusion:
This study describes a large sample of Brazilian
patients with HCV G3.
Treatment patterns were mainly influenced by the presence of HCV
complications and comorbidities.(AU)